ArticleCancer discovery2018
Screening Tool for Gynecologic Cancers Assessed.
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients.Journal of clinical medicine · 2021Review
Corrections and comments
- Comment on
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Researchers have developed a test called PapSEEK that detects endometrial and ovarian cancers by analyzing DNA samples for mutations and aberrations in chromosome number. In a large, retrospective study, the test detected 81% of endometrial cancers and 33% of ovarian cancers with a low false-positive rate.
Indexed as
Identifiers
29615402What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.